Axsome Therapeutics AXSM Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's total cost of revenue?
- Axsome Therapeutics (AXSM) reported total cost of revenue of $14.73M in Q1 2026.
- How has Axsome Therapeutics's total cost of revenue changed year-over-year?
- Axsome Therapeutics's total cost of revenue increased by 50.4% year-over-year, from $9.79M to $14.73M.
- What is the long-term trend for Axsome Therapeutics's total cost of revenue?
- Over 3 years (2022 to 2025), Axsome Therapeutics's total cost of revenue has grown at a 109.0% compound annual growth rate (CAGR), from $5.2M to $47.48M.
- What does total cost of revenue mean?
- The direct costs incurred to produce and deliver the goods or services sold by the company.
- How do you interpret total cost of revenue?
- A decrease relative to revenue indicates improved manufacturing efficiency or economies of scale, while an increase may signal rising production costs.
- How does total cost of revenue compare across companies?
- Varies by product type; generally lower for companies with high-margin specialty drugs compared to generic manufacturers.